31
total announcements
MARKSANS.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹14,236 Cr
P/E (TTM)
27.5
P/E (Forward)
22.3
EPS (TTM)
₹11.41
52W Low
₹155.00
52W High
₹350.95
Dividend Yield
0.28%
Beta
1.15
Price / Book
4.7
Debt / Equity
11.2
Revenue (TTM)
₹3,172 Cr
Gross Margin
55.24%
Operating Margin
22.38%
Marksans Pharma Limited
Marksans Pharma Limited has received a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities up to September 30, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange regarding the opening of a special window for re-lodgment of transfer requests of physical shares, as per SEBI's Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about a newspaper publication regarding the transfer of unclaimed dividend and equity shares to the Investor Education and Protection Fund (IEPF).
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about Schedule of Investors Meet to be held on 2nd September 2026 at Hyatt, Santacruz East, Mumbai.
Marksans Pharma Limited
Marksans Pharma Limited has submitted the Exchange a copy Srutinizers report along with voting result of Annual General Meeting held on August 27, 2026. The meeting was held through video conferencing and the results of the voting conducted through remote e-voting and e-voting during the AGM are disclosed.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange regarding Proceedings of 34th Annual General Meeting held on August 27, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has informed the exchange about the ESG score assigned by Crisil ESG Ratings & Analytics Ltd, which is 56 for Fiscal 2026.
Marksans Pharma Limited
Marksans Pharma Limited has announced its Q1 FY27 financial results, with revenue of INR841 crores, up 35.6% year-on-year, and highest-ever quarterly EBITDA of INR213 crores and PAT of INR159 crores. The company has also completed acquisitions in Europe and established a presence in Canada and Ireland.
Marksans Pharma Limited
Marksans Pharma Limited has uploaded the audio recording of its Q1 FY 27 Financial Results investor conference call on its website.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication for Unaudited financial results for the quarter ended June 30, 2026.
Marksans Pharma Limited
Marksans Pharma reported Q1FY27 financial results with record profitability, with EBITDA rising 113% YoY to ₹213 crore and PAT growing 174% YoY to ₹159 crore. The company also achieved its highest-ever quarterly revenue of ₹841 crore and crossed ₹1,000 crore in cash balance for the first time.
Marksans Pharma Limited
Marksans Pharma Limited has released its Q1FY27 investor presentation, highlighting a strong start to the year with all-time high quarterly EBITDA of ₹213 crore and PAT of ₹159 crore.
Marksans Pharma Limited
Marksans Pharma Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, which have been approved by the Board of Directors. The results are available on the company's website.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding Notice of 34th AGM, record date and e-voting information published in Business Standard and Lakshadeep newspapers.
Marksans Pharma Limited
Marksans Pharma Limited has submitted its Business Responsibility and Sustainability Report for the financial year 2025-26, as per the provisions of Regulation 34 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 27, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has scheduled a conference call on August 13, 2026, to discuss its unaudited financial results for the quarter ended June 30, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication for AGM Intimation, regarding 34th Annual General Meeting scheduled to be held on August 27, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about the acquisition of 100 percent share capital of ABCnow GmbH, a German company.